NatureWise’s new chemical entity, NBM-MBX, received US Food and Drug Administration (FDA) approval on July 24th to proceed Phase I clinical trial. NBM-MBX is an isoform-selective histone deacetylase 8 (HDAC 8) inhibitor. The high specificity produces less side effects than those of non-selective HDAC inhibitors. […]
The Biotechnology Innovation Organization (BIO) is holding its 2018 International Convention from June 4 to 7 in Boston, MA, USA. […]
The Israeli’s Patent Office approved the application of “PRENYLFLAVANONE COMPOUNDS FOR MODULATING DIABETES” from NBM for an invention patent with the certificate No. 231754. Prenylflavanone compounds have been used in NBM’s product, SugarBless, for blood sugar control.
The US Patent Invention No. 14/632,894 "EXTRACT OF TAIWANESE PROPOLIS FOR TREATING OCULAR DISEASES" filed by NatureWise was approved by the U.S. Patent and Trademark Office. Frequent usage of 3C products lead to eye damage. Our extract of Taiwanese green propolis has been found to protect the eye.
“NBM-BMX, a specific histone deacetylase 8 inhibitor, developed solely by NBM from scratch, has met the requirements by the "Biotech New Drug Industry Development Regulations" and other related provisions, to be recognized as an innovative new drug by Industrial Development Bureau, Ministry of Economic Affairs. With the endorsement, the company can get a number of tax-favored benefits.
NatureWise will commercially develop HDAC8 inhibitors patented by City of Hope, collaborators. City of Hope today announced that it has licensed its HDAC8 inhibitors patent exclusively to NatureWise Biotech & Medicals Corporation, a pharmaceutical company in Taipei, Taiwan. Read more: https://www.cityofhope.org/news/city-of-hope-naturewise-announce-license-agreement
